Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 21, 2017; 23(31): 5764-5772
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5764
Figure 4
Figure 4 Relapse-free survival of patients according to doublecortin and CaM kinase-like-1 expression, excluding patients with macroscopic residual tumor. A: RFS of patients with DCLK1 positivity was 10.2 mo; B: That of patients with DCLK1 negativity was 25.5 mo. Relapse of patients with DCLK1 positivity was significantly shorter than that of patients with DCLK1 negativity (P = 0.0005). DCLK1: Doublecortin and CaM kinase-like-1; RFS: Relapse-free survival.